Neurobiology of Aging
Volume 28, Issue 4 , Pages 537-547 , April 2007

Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis

  • Francine Gervais

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • Present address: Painceptor Pharma Corp., 7150, Albert-Einstein, suite 100, Saint-Laurent, QC, Canada H4S 2C1.
    • ,
  • Julie Paquette

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • ,
  • Céline Morissette

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • ,
  • Pascale Krzywkowski

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • ,
  • Mathilde Yu

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • ,
  • Mounia Azzi

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • ,
  • Diane Lacombe

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • ,
  • Xianqi Kong

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • Corresponding Author InformationCorresponding author. Tel.: +1 450 680 4500; fax: +1 450 680 4676.
    • ,
  • Ahmed Aman

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • ,
  • Julie Laurin

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • ,
  • Walter A. Szarek

      Affiliations

    • Department of Chemistry, Queen's University, 99 University Ave., Kingston, ON, Canada K7L 3N6
    • ,
  • Patrick Tremblay

      Affiliations

    • Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7
    • Present address: Bioaxone Therapeutic Inc., 7150 Frederick-Banting, Suite 200, Saint-Laurent, QC, Canada H4S 2A1.

Received 17 August 2005 ,Revised 22 December 2005 ,Accepted 16 February 2006.

References 

  1. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–919
  2. Barghorn S, Nimmrich V, Striebinger A, et al. Globular amyloid beta-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem. 2005;95:834–847
  3. Bitan G, Kirkitadze MD, Lomakin A, et al. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA. 2003;100:330–335
  4. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30:665–676
  5. Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562–21570
  6. Conway KA, Baxter EW, Felsenstein KM, Reitz AB. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Des. 2003;9:427–447
  7. Cotman SL, Halfter W, Cole GJ. Agrin binds to beta-amyloid (Abeta), accelerates Abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Mol Cell Neurosci. 2000;15:183–198
  8. De Jonghe C, Esselens C, Kumar-Singh S, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001;10:1665–1671
  9. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850–8855
  10. Dodart JC, Mathis C, Bales KR, Paul SM. Does my mouse have Alzheimer's disease?. Genes Brain Behav. 2002;1:142–155
  11. Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710–713
  12. El Idrissi A, Trenkner E. Taurine as a modulator of excitatory and inhibitory neurotransmission. Neurochem Res. 2004;29:189–197
  13. Fraser PE, Nguyen JT, Chin DT, Kirschner DA. Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem. 1992;59:1531–1540
  14. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523–527
  15. Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid. 2001;8:28–35
  16. Gervais F, Garceau D, Aisen PS, Gauthier S. Glycosaminoglycan mimetics in Alzheimer's disease. In:  Gauthier S,  Scheltens P,  Cummings JL editor. Alzheimer's disease and related disorders annual 5. London: Taylor & Francis; 2006;p. 63–72
  17. Ghiso J, Shayo M, Calero M, et al. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem. 2004;279:45897–45908
  18. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704–706
  19. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003;100:10417–10422
  20. Gupta-Bansal R, Frederickson RCA, Brunden KR. Proteoglycan-mediated inhibition of Abeta proteolysis: a potential cause of senile plaque accumulation. J Biol Chem. 1995;270:18666–18671
  21. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356
  22. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184–185
  23. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102
  24. Janus C, Pearson J, McLaurin J, et al. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979–982
  25. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32:4693–4697
  26. Kisilevsky R, Fraser PE. Abeta amyloidogenesis: unique, or variation on a systemic theme?. Crit Rev Biochem Mol Biol. 1997;32:361–404
  27. Kroger S, Schroder JE. Agrin in the developing CNS: new roles for a synapse organizer. News Physiol Sci. 2002;17:207–212
  28. Lahiri DK, Farlow MR, Sambamurti K, et al. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets. 2003;4:97–112
  29. Leveugle B, Ding W, Durkin JT, et al. Heparin promotes β-secretase cleavage of the Alzheimer's amyloid precursor protein. Neurochem Int. 1997;30:543–548
  30. Leveugle B, Ding W, Laurence F, et al. Heparin oligosaccharides that pass the blood-brain barrier inhibit β-amyloid precursor protein secretion and heparin binding to β-amyloid peptide. J Neurochem. 1998;70:736–744
  31. Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer's disease locus on chromosome 1. Science. 1995;269:970–973
  32. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709–5714
  33. Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 2001;22:983–991
  34. Louzada PR, Lima AC, Mendonca-Silva DL, et al. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J. 2004;18:511–518
  35. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853–862
  36. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860–866
  37. Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982–985
  38. Proudfoot AE, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA. 2003;100:1885–1890
  39. Raman R, Sasisekharan V, Sasisekharan R. Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol. 2005;12:267–277
  40. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376:775–778
  41. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromol Med. 2002;1:1–31
  42. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–177
  43. Scholefield Z, Yates EA, Wayne G, et al. Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. J Cell Biol. 2003;163:97–107
  44. Schulz JG, Megow D, Reszka R, et al. Evidence that glypican is a receptor mediating beta-amyloid neurotoxicity in PC12 cells. Eur J Neurosci. 1998;10:2085–2093
  45. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–766
  46. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1997;275:630–631
  47. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754–760
  48. Sisodia SS, St. George-Hyslop PH. Gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?. Nat Rev Neurosci. 2002;3:281–290
  49. van Groen T, Kadish I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res Brain Res Rev. 2005;48:370–378
  50. Verbeek MM, Otte-Holler I, van den Born J, et al. Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. Am J Pathol. 1999;155:2115–2125
  51. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–539
  52. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181–193
  53. Watanabe N, Araki W, Chui DH, et al. Glypican-1 as an Abeta binding HSPG in the human brain: its localization in DIG domains and possible roles in the pathogenesis of Alzheimer's disease. FASEB J. 2004;18:1013–1015
  54. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212–216
  55. Wisniewski HM, Wegiel J. The neuropathology of Alzheimer's disease. Neuroimag Clin N Am. 1995;5:45–57
  56. Zornoza T, Cano MJ, Polache A, Granero L. Pharmacology of acamprosate: an overview. CNS Drug Rev. 2003;9:359–374

PII: S0197-4580(06)00079-0

doi: 10.1016/j.neurobiolaging.2006.02.015

Neurobiology of Aging
Volume 28, Issue 4 , Pages 537-547 , April 2007

Article Tools

* Image Usage & Resolution